1. Leemans CR, Snijders PJF and Brakenhoff RH: The molecular land‑
scape of head and neck cancer. Nat Rev Cancer 18: 269‑282, 2018.
2. de Martel C, Plummer M, Vignat J and Franceschi S: Worldwide
burden of cancer attributable to HPV by site, country and HPV
type. Int J Cancer 141: 664‑670, 2017.
3. Van Doorslaer K, Chen Z, Bernard HU, Chan PKS, DeSalle R,
Dillner J, Forslund O, Haga T, McBride AA, Villa LL, et al:
ICTV virus taxonomy profile: Papillomaviridae. J Gen Virol 99:
989‑990, 2018.
4. Kumar A, Rathi E, Hariharapura RC and Kini SG: Is viral E6
oncoprotein a viable target? A critical analysis in the context of
cervical cancer. Med Res Rev 40: 2019‑2048, 2020.
5. Marur S, D'Souza G, Westra WH and Forastiere AA:
HPV‑associated head and neck cancer: A virus‑related cancer
epidemic. Lancet Oncol 11: 781‑789, 2010.
6. Carrero I, Liu HC, Sikora AG and Milosavljevic A: Histoepigenetic
analysis of HPV‑ and tobacco‑associated head and neck cancer iden‑
tifies both subtype‑specific and common therapeutic targets despite
divergent microenvironments. Oncogene 38: 3551‑3568, 2019.
7. Kamizaki K, Endo M, Minami Y and Kobayashi Y: Role of
noncanonical Wnt ligands and Ror‑family receptor tyrosine
kinases in the development, regeneration, and diseases of the
musculoskeletal system. Dev Dyn 250: 27‑38, 2021.
8. Huang J, Shi Y, Li H, Tan D, Yang M and Wu X: Knockdown of
receptor tyrosine kinase‑like orphan receptor 2 inhibits cell prolif‑
eration and colony formation in osteosarcoma cells by inducing
arrest in cell cycle progression. Oncol Lett 10: 3705‑3711, 2015.
ONCOLOGY REPORTS 46: 148, 2021
9. Yan L, Du Q, Yao J and Liu R: ROR2 inhibits the proliferation
of gastric carcinoma cells via activation of non‑canonical Wnt
signaling. Exp Ther Med 12: 4128‑4134, 2016.
10. Saji T, Nishita M, Ogawa H, Doi T, Sakai Y, Maniwa Y and
Minami Y: Critical role of the Ror‑family of receptor tyrosine
kinases in invasion and proliferation of malignant pleural meso‑
thelioma cells. Genes Cells 23: 606‑613, 2018.
11. Endo M, Tanaka Y, Otsuka M and Minami Y: E2F1‑Ror2
signaling mediates coordinated transcriptional regulation to
promote G1/S phase transition in bFGF‑stimulated NIH/3T3
fibroblasts. FASEB J 34: 3413‑3428, 2020.
12. Kobayashi M, Shibuya Y, Takeuchi J, Murata M, Suzuki H,
Yokoo S, Umeda M, Minami Y and Komori T: Ror2 expression
in squamous cell carcinoma and epithelial dysplasia of the oral
cavity. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 107:
398‑406, 2009.
13. Enomoto M, Hayakawa S, Itsukushima S, Ren DY, Matsuo M,
Tamada K, Oneyama C, Okada M, Takumi T, Nishita M and
Minami Y: Autonomous regulation of osteosarcoma cell invasive‑
ness by Wnt5a/Ror2 signaling. Oncogene 28: 3197‑3208, 2009.
14. Aoki T, Nishita M, Sonoda J, Ikeda T, Kakeji Y and Minami Y:
Intraflagellar transport 20 promotes collective cancer cell inva‑
sion by regulating polarized organization of Golgi‑associated
microtubules. Cancer Sci 110: 1306‑1316, 2019.
15. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE,
Brookland RK, Meyer L, Gress DM, Byrd DR and Winchester DP:
The Eighth edition AJCC Cancer Staging Manual: Continuing to
build a bridge from a population‑based to a more ‘personalized’
approach to cancer staging. CA Cancer J Clin 67: 93‑99, 2017.
16. Tao X, Zheng B, Yin F, Zeng Z, Li Z, Griffith CC, Luo B, Ding X,
Zhou X and Zhao C: Polymerase Chain reaction human papil‑
lomavirus (HPV) detection and HPV genotyping in invasive
cervical cancers with prior negative HC2 test results. Am J Clin
Pathol 147: 477‑483, 2017.
17. Livak KJ and Schmittgen TD: Analysis of relative gene expres‑
sion data using real‑time quantitative PCR and the 2(‑Delta Delta
C(T)) method. Methods 25: 402‑408, 2001.
18. Hoppe‑Seyler K, Bossler F, Braun JA, Herrmann AL and
Hoppe‑Seyler F: The HPV E6/E7 oncogenes: Key factors for viral
carcinogenesis and therapeutic targets. Trends Microbiol 26:
158‑168, 2018.
19. Lee SH, Lee CR, Rigas NK, Kim RH, Kang MK, Park NH and
Shin KH: Human papillomavirus 16 (HPV16) enhances tumor
growth and cancer stemness of HPV‑negative oral/oropharyn‑
geal squamous cell carcinoma cells via miR‑181 regulation.
Papillomavirus Res 1: 116‑125, 2015.
20. Jiang Z, Jiang C, Yu C and Fang J: MicroRNA‑208b inhibits
human osteosarcoma progression by targeting ROR2. Tumour
Biol 39: 1010428317705751, 2017.
21. Benson E, Li R, Eisele D and Fakhry C: The clinical impact
of HPV tumor status upon head and neck squamous cell carci‑
nomas. Oral Oncol 50: 565‑574, 2014.
22. O'Connell MP, Fiori JL, Xu M, Carter AD, Frank BP, Camilli TC,
French AD, Dissanayake SK, Indig FE, Bernier M, et al: The
orphan tyrosine kinase receptor, ROR2, mediates Wnt5A
signaling in metastatic melanoma. Oncogene 29: 34‑44, 2010.
23. Xu J, Shi J, Tang W, Jiang P, Guo M, Zhang B and Ma G:
ROR2 promotes the epithelial‑mesenchymal transition by regu‑
lating MAPK/p38 signaling pathway in breast cancer. J Cell
Biochem 121: 4142‑4153, 2020.
24. Rasmussen NR, Debebe Z, Wright TM, Brooks SA, Sendor AB,
Brannon AR, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboli P, et al:
Expression of Ror2 mediates invasive phenotypes in renal cell
carcinoma. PLoS One 9: e116101, 2014.
25. Yeo‑Teh NSL, Ito Y and Jha S: High‑risk human papillomaviral
oncogenes E6 and E7 target key cellular pathways to achieve
oncogenesis. Int J Mol Sci 19: 1706, 2018.
26. Charette ST and McCance DJ: The E7 protein from human
papillomavirus type 16 enhances keratinocyte migration in an
Akt‑dependent manner. Oncogene 26: 7386‑7390, 2007.
27. Carrillo D, Muñoz JP, Huerta H, Leal G, Corvalán A, León O,
Calaf GM, Urzúa U, Boccardo E, Tapia JC and Aguayo F:
Upregulation of PIR gene expression induced by human papil‑
lomavirus E6 and E7 in epithelial oral and cervical cells. Open
Biol 7: 170111, 2017.
28. Ikeda T, Nishita M, Hoshi K, Honda T, Kakeji Y and Minami Y:
Mesenchymal stem cell‑derived CXCL16 promotes progression
of gastric cancer cells by STAT3‑mediated expression of Ror1.
Cancer Sci 111: 1254‑1265, 2020.
29. zur Hausen H: Papillomaviruses and cancer: From basic studies
to clinical application. Nat Rev Cancer 2: 342‑350, 2002.
...
論文の公開元へ
